Wald: it is planning to buy xinjinquan shares by issuing shares and paying cash. The trading of shares is suspended

Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum

A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.

Temu Expands Slovenian Seller Network as EU Tightens Cross-Border E-Commerce Rules

Temu（拼多多海外电商平台）, the cross-border marketplace backed by PDD Holdings（拼多多控股）, is expanding its local-seller and logistics footprint in Slovenia, positioning itself for a European market where low-value imports face new customs costs and online marketplaces face tougher accountability rules.

China-Built Vehicles Overtake German-Made Cars as South Korea’s Top Import Source

China has overtaken Germany as South Korea’s largest source of imported vehicles by manufacturing origin for the first time, as Shanghai-built Tesla models and expanding sales by BYD reshape one of Asia’s most competitive car markets.

Unpacking China | Key Chinese Firms to Watch This Week （26/07/2026-01/08/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion

Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.